Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Why Pfizer (PFE) Outpaced the Stock Market Today
06:45pm, Wednesday, 01'st Apr 2026
In the most recent trading session, Pfizer (PFE) closed at $28.55, indicating a +1.67% shift from the previous trading day.
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
12:25pm, Wednesday, 01'st Apr 2026
Pfizer's PFE stock has been trading steadily above its 50-day and 200-day simple moving averages (SMAs) since early January, signaling sustained investor confidence. The stock is also up about 12.8% s
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
11:39am, Wednesday, 01'st Apr 2026
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
10:13am, Wednesday, 01'st Apr 2026
A Belgian court on Wednesday ordered Poland and Romania to take delivery of 1.9 billion euros ($2.2 billion) worth of COVID-19 vaccines made by U.S. drugmaker Pfizer.
Pfizer Pulls Back From South San Francisco
08:30am, Wednesday, 01'st Apr 2026
Pfizer (PFE, Financials) is getting ready to close its research site and office in South San Francisco at the end of April. This seems like a big step back from
Pfizer Inc. $PFE Shares Sold by Frank Rimerman Advisors LLC
07:24am, Wednesday, 01'st Apr 2026
Frank Rimerman Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE: PFE) by 16.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commissio
Cherry Creek Investment Advisors Inc. Acquires New Position in Pfizer Inc. $PFE
06:02am, Wednesday, 01'st Apr 2026
Cherry Creek Investment Advisors Inc. bought a new position in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor b
25,590 Shares in Pfizer Inc. $PFE Purchased by Econ Financial Services Corp
04:50am, Wednesday, 01'st Apr 2026
Econ Financial Services Corp acquired a new stake in shares of Pfizer Inc. (NYSE: PFE) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 25,590
Fifth Third Wealth Advisors LLC Buys 22,405 Shares of Pfizer Inc. $PFE
04:17am, Wednesday, 01'st Apr 2026
Fifth Third Wealth Advisors LLC raised its position in shares of Pfizer Inc. (NYSE: PFE) by 15.1% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
10:00am, Monday, 30'th Mar 2026
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Prediction: Buying Pfizer Stock Today Could Set You Up for Life
08:15pm, Sunday, 29'th Mar 2026
Pfizer has a proven track record of success in the pharmaceutical sector. Management has shown, once again, that it can pivot quickly when needed.
Chesley Taft & Associates LLC Acquires 60,956 Shares of Pfizer Inc. $PFE
05:04am, Sunday, 29'th Mar 2026
Chesley Taft and Associates LLC boosted its holdings in Pfizer Inc. (NYSE: PFE) by 41.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Ex
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
02:29am, Sunday, 29'th Mar 2026
Shares of Pfizer Inc. (NYSE: PFE - Get Free Report) have earned an average recommendation of "Hold" from the twenty-three analysts that are covering the company, Marketbeat Ratings reports. Three equi
Pfizer: Why Wall Street Habitually Overestimates Target Price
03:48pm, Friday, 27'th Mar 2026
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models c
Why Pfizer Remains A Strong Buy In 2026
10:46am, Friday, 27'th Mar 2026
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of T
